Targeted Therapies in Cancer:: Myth or Reality? (Google eBook)
Springer Science & Business Media, Dec 5, 2007 - Medical - 200 pages
In September 2005 an International Meeting on “Targeted Therapies in Cancer: Myth or Reality” was held in Milan. This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients. This book collects the contributions given by scientists and clinicians, from Academia and Industry, who participated to this Meeting. We hope that this book contributes to improve our approach to cancer drug discovery and, ultimately, to find new, more efficacious and better tolerated drugs for cancer patients. It provides an overview of diverse approaches ranging from drug discovery to cellular therapy. Although this change in paradigm has been useful, its entry into the clinical arena was associates with unforeseen problems including the emergence of resistance, unexpected side effects and failures. Time is therefore ripe for a critical cultural reflection on the state of the art, prospects and limitations. Ultimately, is targeted therapy in cancer a myth or a reality?
What people are saying - Write a review
We haven't found any reviews in the usual places.
agents analysis angiogenesis anticancer antigen antitumor activity apoptosis assay Aurora kinase Aurora-A Blood c-Met cancer cells Cancer Res carcinoma CD34-TRAIL+ cells CD34+ cells Cdc7 cell lines cellular checkpoint chemokine chemotherapy Chk1 Clin Oncol clinical trials Coiffier compounds cytotoxic disease dose drug discovery efficacy EGFR egfr mutations endothelial cells epidermal growth factor erlotinib expression follicular lymphoma gefitinib gemcitabine gene genetic GIST Glabbeke growth factor receptor human identified Imatinib induced inhibition integrin kinase inhibitor leukemia ligand lung cancer lymphocytes macrophages malignant Mantovani median mice molecular monoclonal antibodies non-Hodgkin’s lymphoma non-small-cell lung cancer NSCLC Oncogene oncology over-expression paradigm pathway patients PDK1 percent Phase II studies phenotype phosphorylation potential progression protein microarrays Proteomics R-CHOP randomized response rituximab role selective signalling small molecule stem cell survival Targeted Therapies therapeutic tissue toxicity TRAIL treated treatment tumor cells tumor growth tyrosine kinase vascular VEGF VEGFR2 Verweij vivo xenografts